In yesterday’s Wall Street session, Taysha Gene Therapies Inc. (NASDAQ:TSHA) shares traded at $3.28, down -2.96% from the previous session.
As we calculate the median target price by taking the range between a high of $8.00 and a low of $2.00, we find $6.00. Given the previous closing price of $3.38, this indicates a potential upside of 77.51 percent. TSHA stock price is now 213.94% away from the 50-day moving average and 164.79% away from the 200-day moving average. The market capitalization of the company currently stands at $646.09M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Brokers who have rated the stock have averaged $5.72 as their price target over the next twelve months.
With the price target reduced from $14 to $1.50, Jefferies Downgraded its rating from Buy to Hold for Taysha Gene Therapies Inc. (NASDAQ: TSHA).
In other news, Alam Kamran, Chief Financial Officer sold 33,000 shares of the company’s stock on Aug 24. The stock was sold for $76,890 at an average price of $2.33. Upon completion of the transaction, the Chief Financial Officer now directly owns 258,042 shares in the company, valued at $0.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 16, 10% Owner Manning Paul B bought 16,466,667 shares of the business’s stock. A total of $14,820,000 was incurred on buying the stock at an average price of $0.90. This leaves the insider owning 16,466,667 shares of the company worth $54.01 million. Insiders disposed of 549,095 shares of company stock worth roughly $1.8 million over the past 1 year. A total of 3.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TSHA stock. A new stake in Taysha Gene Therapies Inc. shares was purchased by SQUAREPOINT OPS LLC during the first quarter worth $264,000. DYNAMIC ADVISOR SOLUTIONS LLC invested $148,000 in shares of TSHA during the first quarter. In total, there are 61 active investors with 23.20% ownership of the company’s stock.
During the past 12 months, Taysha Gene Therapies Inc. has had a low of $0.50 and a high of $4.06. The fifty day moving average price for TSHA is $1.0965 and a two-hundred day moving average price translates $1.2454 for the stock.
The latest earnings results from Taysha Gene Therapies Inc. (NASDAQ: TSHA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.31 by -0.07. This compares to -$0.85 EPS in the same period last year. For the current quarter, analysts expect TSHA to generate $1.32M in revenue.
